About CardioSignal
CardioSignal, developed by Precordior, is a medical software company that has developed a CE-marked Class IIb medical device for detecting atrial fibrillation using smartphone technology. The company's patented gyrocardiography technology utilizes motion sensors built into smartphones to assess precordial micro-vibrations caused by cardiac motion, enabling users to check their heart health in just 60 seconds from anywhere. Based on over 12 years of academic research and validated in clinical studies with 96% accuracy, CardioSignal serves multiple market segments including direct-to-consumer self-monitoring, healthcare providers and insurance companies for population health programs, pharmaceutical companies and CROs for clinical research, and point-of-care clinical settings. The technology has been documented in over 20 peer-reviewed publications and used by more than 200,000 people. CardioSignal is available across 16 European countries and India, offering subscription-based access starting at €3.7 per month. The company is ISO27001-certified for information security and ISO13485-certified as a medical device manufacturer. CardioSignal recently achieved MDR Class IIb certification and is launching CardioSignal Inside, an SDK partnership model that allows B2B partners to integrate the medical-grade atrial fibrillation detection directly into their own mobile applications.
Clinical Focus
Medical conditions and clinical areas addressed by CardioSignal.
Who It Serves
Milestones & Awards
Recent Milestones
Received MDR Class IIb certification (June 2024). Launched CardioSignal Inside SDK partnership model for B2B integration. Won Desafío DKV 2025 at Health4Good in Barcelona. Rolled out first MDR Class IIb app release. Launched AFib case-finding program with LocalTapiola.
Awards & Recognition
Winner of Desafío DKV 2025 at Health4Good Barcelona
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.